Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study)
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study). / Roche, Nicolas; Plaza, Vicente; Backer, Vibeke; Palen, Job van der; Cerveri, Isa; Gonzalez, Chelo; Safioti, Guilherme; Scheepstra, Irma; Patino, Oliver; Singh, Dave.
In: npj Primary Care Respiratory Medicine, Vol. 30, No. 1, 1, 2020.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study)
AU - Roche, Nicolas
AU - Plaza, Vicente
AU - Backer, Vibeke
AU - Palen, Job van der
AU - Cerveri, Isa
AU - Gonzalez, Chelo
AU - Safioti, Guilherme
AU - Scheepstra, Irma
AU - Patino, Oliver
AU - Singh, Dave
N1 - Publisher Copyright: © 2020, The Author(s).
PY - 2020
Y1 - 2020
N2 - Previous studies have found suboptimal control of symptom burden to be widespread among patients with asthma and chronic obstructive pulmonary disease (COPD). The Phase IV SPRINT study was conducted in 10 countries in Europe to assess asthma disease control and COPD symptom burden in patients treated with a fixed-dose combination (FDC) of inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs). SPRINT included 1101 patients with asthma and 560 with COPD; all were receiving treatment with an FDC of ICS/LABA, delivered via various inhalers. Data were obtained over a 3-month period, during a single routine physician’s office visit. Asthma control was defined as Asthma Control Test (ACT) score >19. COPD symptom burden was assessed by COPD Assessment Test (CAT), with a CAT score <10 defining low COPD symptom burden. Among patients using any ICS/LABA FDC, 62% of patients with asthma had achieved disease control (ACT score >19) and 16% of patients with COPD had low symptom burden (CAT score <10).
AB - Previous studies have found suboptimal control of symptom burden to be widespread among patients with asthma and chronic obstructive pulmonary disease (COPD). The Phase IV SPRINT study was conducted in 10 countries in Europe to assess asthma disease control and COPD symptom burden in patients treated with a fixed-dose combination (FDC) of inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs). SPRINT included 1101 patients with asthma and 560 with COPD; all were receiving treatment with an FDC of ICS/LABA, delivered via various inhalers. Data were obtained over a 3-month period, during a single routine physician’s office visit. Asthma control was defined as Asthma Control Test (ACT) score >19. COPD symptom burden was assessed by COPD Assessment Test (CAT), with a CAT score <10 defining low COPD symptom burden. Among patients using any ICS/LABA FDC, 62% of patients with asthma had achieved disease control (ACT score >19) and 16% of patients with COPD had low symptom burden (CAT score <10).
U2 - 10.1038/s41533-019-0159-1
DO - 10.1038/s41533-019-0159-1
M3 - Journal article
C2 - 31911607
AN - SCOPUS:85077642015
VL - 30
JO - Npj Primary Care Respiratory Medicine
JF - Npj Primary Care Respiratory Medicine
SN - 2055-1010
IS - 1
M1 - 1
ER -
ID: 269672862